Ticagrelor

Detailed information about Ticagrelor

CAS Number

274693-27-5

Regulatory Status

CEP : Under assessment

CEP/EDMF

EDMF available

Enquire Now

Innovator Brand

Brilinta

Therapeutic Area

Antiplatelet

USDMF

Others

Enquire Now

Mechanism of Action

Direct-acting, reversibly bound antagonist of the platelet P2Y₁₂ receptor. It prevents adenosine diphosphate (ADP) from binding, which halts downstream signal transduction, platelet activation, and aggregation.

Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement. The liability of any sale into such protected markets is at buyer's risk.

Ready to discuss your needs with us?

Request you to provide all details mentioned in the form along with your business requirement. It will help us route your query to the appropriate person.

Please enter a valid name (only alphabets and spaces allowed).

Please enter your organization name.

Please enter a valid work email address.

Please enter a valid phone number.

Please select your country.

Please enter your message.

By submitting this form you agree to our Privacy Policy concerning the way SCL Lifesciences may use your personal information.

You must agree to the privacy policy.